Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vascular Endothelial Growth Factor (VEGF) Pathway

Vascular Endothelial Growth Factor (VEGF) Pathway PATHWAY OF THE MONTH Monique Nilsson, PhD,* and John V. Heymach, MD, PhD*† (J Thorac Oncol. 2006;1: 768–770) onstrated to be coreceptors for VEGF. NRP-1 binds VEGF and PlGF, and NRP-2 binds VEGF165 and VEGF-C. Unlike other VEGFRs, NRP-1,2 lack intracellular signaling do- ngiogenesis, the growth of new capillary blood vessels, mains. Although the specific role of NRP-1,2 in angiogenesis Ais critical for the growth and metastatic spread of is not fully known, NRP-1,2 bind VEGF ligands and enhance 1 8 tumors. The search for tumor-derived factors that stimu- their affinity to other VEGFRs. late angiogenesis led to the identification of vascular endothelial growth factor (VEGF, also known as VEGF-A) as an endothelial mitogen. This protein had previously VEGF SIGNAL TRANSDUCTION been identified as vascular permeability-inducing factor Although VEGF-A binds VEGFR1 with a higher affin- secreted by tumor cells (VPF, for vascular permeability ity than VEGFR-2, the biological effects of VEGF-A are factor). The VEGF gene undergoes alternative splicing to thought to be mediated through VEGFR-2. On ligand bind- yield at least five different isoforms, ranging in size from ing, VEGFR-2 dimerizes, resulting in kinase activation and 121 to 206 amino acids, of which VEGF is the predom- autophosphorylation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Vascular Endothelial Growth Factor (VEGF) Pathway

Heymach, John V.
Journal of Thoracic Oncology , Volume 1 (8) – Oct 1, 2006
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/vascular-endothelial-growth-factor-vegf-pathway-qwLIUoCXXe

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

PATHWAY OF THE MONTH Monique Nilsson, PhD,* and John V. Heymach, MD, PhD*† (J Thorac Oncol. 2006;1: 768–770) onstrated to be coreceptors for VEGF. NRP-1 binds VEGF and PlGF, and NRP-2 binds VEGF165 and VEGF-C. Unlike other VEGFRs, NRP-1,2 lack intracellular signaling do- ngiogenesis, the growth of new capillary blood vessels, mains. Although the specific role of NRP-1,2 in angiogenesis Ais critical for the growth and metastatic spread of is not fully known, NRP-1,2 bind VEGF ligands and enhance 1 8 tumors. The search for tumor-derived factors that stimu- their affinity to other VEGFRs. late angiogenesis led to the identification of vascular endothelial growth factor (VEGF, also known as VEGF-A) as an endothelial mitogen. This protein had previously VEGF SIGNAL TRANSDUCTION been identified as vascular permeability-inducing factor Although VEGF-A binds VEGFR1 with a higher affin- secreted by tumor cells (VPF, for vascular permeability ity than VEGFR-2, the biological effects of VEGF-A are factor). The VEGF gene undergoes alternative splicing to thought to be mediated through VEGFR-2. On ligand bind- yield at least five different isoforms, ranging in size from ing, VEGFR-2 dimerizes, resulting in kinase activation and 121 to 206 amino acids, of which VEGF is the predom- autophosphorylation

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Oct 1, 2006

There are no references for this article.